Related Experiment Video

Updated: Jan 22, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Istaroxime - update of data in early cardiogenic shock and decompensated heart failure

Kamila Florek1, Wojciech Zimoch1, Jan Biegus1

  • 1Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.

Expert Opinion on Investigational Drugs
|January 20, 2026
PubMed

Insights

Istaroxime shows promise for treating cardiogenic shock (CS) by improving hemodynamics without increasing heart rate. This novel inotrope offers a safer alternative to traditional treatments for acute heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiogenic shock (CS) is a severe form of acute heart failure (AHF) with high mortality rates.
  • Current inotropes carry risks like arrhythmias and ischemia, necessitating safer alternatives.
  • Early intervention in CS is crucial before neurohumoral and inflammatory changes occur.

Purpose of the Study:

  • To elucidate the mechanism of action of istaroxime.
  • To evaluate the efficacy and safety of istaroxime in early-stage CS patients through Phase II trials.

Main Methods:

  • Review of istaroxime's pharmacological profile.
  • Analysis of data from Phase II clinical trials involving patients with early cardiogenic shock.

Main Results:

  • Istaroxime demonstrated significant hemodynamic improvements in early CS.
  • The drug effectively increased systolic blood pressure and enhanced cardiac function.
  • Istaroxime exhibited a favorable safety profile, with a lower risk of arrhythmias compared to existing inotropes.
  • Its unique ino-lusitropic mechanism improved cardiac performance without increasing heart rate.

Conclusions:

  • Istaroxime is an effective treatment for early cardiogenic shock.
  • Its unique mechanism and safety profile present advantages over traditional inotropic agents.
  • Istaroxime represents a promising therapeutic option for managing AHF and CS.
Abstract

Keywords:
Cardiogenic shockcentral hemodynamicsclinical trialsinotropesistaroxime

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.1K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227